Cantargia AB (FRA:7V3)
€ 0.1378 0.0033 (2.45%) Market Cap: 28.81 Mil Enterprise Value: 23.62 Mil PE Ratio: 0 PB Ratio: 6.87 GF Score: 38/100

Cantargia AB Briefing on Update Recently Announced Rights Issue Transcript

Jul 07, 2022 / 12:00PM GMT
Release Date Price: €0.530764 (+0.23%)
Tara Sobierajski
LifeSci Advisors, LLC - Event Coordinator

Good morning and welcome to the Cantargia Shareholder Briefing on Rights Issue. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the Cantargia website following the conclusion of the event.

I'd now like to turn the call over to Dr. Göran Forsberg, Chief Executive Officer of Cantargia. Please go ahead, Göran.

GÃ;ran Forsberg
Cantargia AB - CEO

¶ -

[Thank you so much.] It's a pleasure to have you all attending this briefing ahead of our proposed drug rights issue, and I will take you a little bit through this rights issue, why we're doing it, and let's say, where we come from. I really think we come from a position of strength here and moving forward.

So the background is very much that we presented new very exciting results using our lead asset, nadunolimab, at the international ASCO conference earlier on in June.

And we obviously realized that this presentation gave very increased international

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot